ArticleAmerican journal of translational research2025
Ultrasound-guided stellate ganglion block with ropivacaine for postpartum depression.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Superior autonomic regulation with ropivacaine over lidocaine in stellate ganglion block for chronic insomnia: a randomized controlled trial.BMC anesthesiology · 2026Trial
- Observational
- Advances in the clinical application of stellate ganglion block for non-pain indications.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy of ultrasound-guided stellate ganglion block (SGB) with ropivacaine in treating postpartum depression.
methodsA retrospective analysis was conducted on the medical records of 98 patients from Ordos Central Hospital, treated between January 2020 and December 2022. Patients were divided into two groups: with 42 patients receiving escitalopram oxalate tablets (escitalopram group) and 56 patients undergoing ultrasound-guided SGB with ropivacaine (ropivacaine group). The therapeutic effects, depression, sleep status, and stress levels before and after treatment were compared. Logistic regression analysis was performed to identify risk factors for postpartum depression recovery.
resultsPost-treatment, the Hamilton Depression Rating Scale (HAMD), Edinburgh Postpartum Depression Scale (EPDS), and Pittsburgh Sleep Quality Index (PSQI) scores decreased significantly in both groups, with the ropivacaine group showing greater improvements (all P < 0.05). Additionally, the levels of adrenocorticotropic hormone (ACTH), corticotropin-releasing hormone (CRH), and cortisol (Cor) were significantly lower in the ropivacaine group compared to the escitalopram group (all P < 0.05). The total effective rate was higher in the ropivacaine group than in the escitalopram group (P < 0.05). Logistic multivariate regression identified mode of delivery, household economic status, marital relationship, frequency of exercise during the second trimester, and treatment mode as independent risk factors for postpartum depression recovery (all P < 0.05).
conclusionUltrasound-guided SGB with ropivacaine is an effective treatment for postpartum depression, significantly alleviating depression symptoms, improving sleep quality, and reducing stress levels. This treatment is recommended for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.